AKR1A1 and Kidney Disease: Promise and Perils of the Multiverse

Matthew D. Breyer
DOI: https://doi.org/10.2337/dbi24-0022
IF: 7.7
2024-06-21
Diabetes
Abstract:Past years have seen a proliferation of omics-related databases, such as genomics, epigenomics, transcriptomics, proteomics, and metabolomics databases, that provide huge data sets with millions, if not billions, of potential associations with disease phenotypes. Genomics alone are seldom sufficient to identify the role of gene polymorphisms in the pathogenesis of diseases, as exemplified by two of the strongest genetic associations in metabolic diseases: TCF7L2 in type 2 diabetes and UMOD in chronic kidney disease (CKD). Diverse functions have been attributed to each of these proteins (1,2), but which of these functions might be relevant to therapeutically target for disease mitigation is unclear. Furthermore, gene polymorphisms often do not alter protein-coding sequence or are in noncoding regions of the genome, where their effects on protein expression level is unclear.
endocrinology & metabolism
What problem does this paper attempt to address?